Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zoligratinib - Debiopharm

Next Previous
Drug Profile

Zoligratinib - Debiopharm

Alternative Names: CH 5183284; DEBIO-1347; Debio1347; FF 284

Latest Information Update: 28 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Debiopharm
  • Class Amines; Antineoplastics; Benzimidazoles; Indoles; Ketones; Pyrazoles; Small molecules
  • Mechanism of Action Signal transduction pathway inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Breast cancer

Most Recent Events

  • 28 Mar 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Singapore (PO)
  • 28 Mar 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in South Korea (PO)
  • 28 Mar 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Spain (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top